BeOne Medicines Ltd. (NASDAQ:ONC) ranks among the best biotech stocks to buy. On September 18, Barclays began coverage of BeOne Medicines Ltd. (NASDAQ:ONC), rating it Overweight and setting a price target of $385 on the company’s shares. The firm cited two anticipated “value-inflecting pivotal data readouts” that might propel the oncology company’s growth. The first projected catalyst is data on BeOne’s BTK inhibitor in first-line mantle cell lymphoma, which is due in the latter half of 2025. Barclays al ...